USD
+$0.00
(+0.00%
)At Close (As of Sep 17, 2025)
$152.93M
Market Cap
-
P/E Ratio
-0.19
EPS
$3.33
52 Week High
$1.12
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $65M |
Total Revenue | $86M |
Cost Of Revenue | $20M |
Costof Goods And Services Sold | $20M |
Operating Income | $8.2M |
Selling General And Administrative | $15M |
Research And Development | $17M |
Operating Expenses | $57M |
Investment Income Net | - |
Net Interest Income | -$9M |
Interest Income | $1.5M |
Interest Expense | $10M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.8M |
Income Before Tax | -$6.3M |
Income Tax Expense | $2M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$8.3M |
Comprehensive Income Net Of Tax | - |
Ebit | $4.1M |
Ebitda | $6.9M |
Net Income | -$8.3M |
Field | Value (USD) |
---|---|
Total Assets | $53M |
Total Current Assets | $44M |
Cash And Cash Equivalents At Carrying Value | $5.9M |
Cash And Short Term Investments | $5.9M |
Inventory | $5.3M |
Current Net Receivables | $16M |
Total Non Current Assets | $9.4M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $7.6M |
Intangible Assets Excluding Goodwill | $7.6M |
Goodwill | - |
Investments | - |
Long Term Investments | $214K |
Short Term Investments | $3.7M |
Other Current Assets | $14M |
Other Non Current Assets | - |
Total Liabilities | $79M |
Total Current Liabilities | $37M |
Current Accounts Payable | $6.3M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $3.9M |
Total Non Current Liabilities | $42M |
Capital Lease Obligations | $1.2M |
Long Term Debt | $41M |
Current Long Term Debt | $3.5M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $46M |
Other Current Liabilities | $27M |
Other Non Current Liabilities | $21K |
Total Shareholder Equity | -$25M |
Treasury Stock | - |
Retained Earnings | -$417M |
Common Stock | $364M |
Common Stock Shares Outstanding | $49M |
Field | Value (USD) |
---|---|
Operating Cashflow | $2.4M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $2.8M |
Capital Expenditures | $1.5M |
Change In Receivables | - |
Change In Inventory | $785K |
Profit Loss | - |
Cashflow From Investment | $942K |
Cashflow From Financing | -$21M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$8.3M |
Field | Value (USD) |
---|---|
Gross Profit | $65M |
Total Revenue | $86M |
Cost Of Revenue | $20M |
Costof Goods And Services Sold | $20M |
Operating Income | $8.2M |
Selling General And Administrative | $15M |
Research And Development | $17M |
Operating Expenses | $57M |
Investment Income Net | - |
Net Interest Income | -$9M |
Interest Income | $1.5M |
Interest Expense | $10M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.8M |
Income Before Tax | -$6.3M |
Income Tax Expense | $2M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$8.3M |
Comprehensive Income Net Of Tax | - |
Ebit | $4.1M |
Ebitda | $6.9M |
Net Income | -$8.3M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Theratechnologies Inc. (THTX) is a Montreal-based biopharmaceutical company dedicated to developing and commercializing innovative therapies tailored to address significant unmet medical needs, particularly in the fields of HIV, oncology, and metabolic disorders. With a strategic focus on specialized drug delivery systems and targeted therapies, Theratechnologies aims to improve patient outcomes across North America and Europe. Boasting a robust pipeline of clinical and preclinical candidates, the company is well-positioned to leverage its expertise in biopharmaceutical development to enhance its market presence and drive sustainable growth.